Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor

被引：0
|
作者：
Yamauchi, Keishi
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-798-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798-P
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Hepatic fat deposition is improved more with SGLT2 inhibitor luseogliflozin compared with sitagliptin: a randomised, crossover, controlled study using computed tomography
    Fushimi, N.
    Shibuya, T.
    Takeishi, S.
    Itou, S.
    Kawai, H.
    Mori, A.
    DIABETOLOGIA, 2015, 58 : S392 - S392
  • [42] Low-Carbohydrate Diet Did Not Affect the Behavior of Luseogliflozin, a Selective SGLT2 Inhibitor, on Glycemic Control over 24 Hours Measured by Continuous Glucose Monitoring (CGM) in Japanese Patients with Type 2 Diabetes
    Nishimura, Rimei
    Osonoi, Takeshi
    Jinnouchi, Hideaki
    Kanada, Shigeto
    Sakai, Soichi
    Samukawa, Yoshishige
    DIABETES, 2015, 64 : A240 - A240
  • [43] The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
    Chu, Chang
    Lu, Yong-Ping
    Yin, Lianghong
    Hocher, Berthold
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (02): : 149 - 157
  • [44] The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
    Day, Emily A.
    Ford, Rebecca J.
    Lu, Jessie H.
    Lu, Rachel
    Lundenberg, Lucie
    Desjardins, Eric M.
    Green, Alex E.
    Lally, James S., V
    Schertzer, Jonathan D.
    Steinberg, Gregory R.
    BIOCHEMICAL JOURNAL, 2020, 477 (12) : 2347 - 2361
  • [45] DAPAGLIFLOZIN, A SELECTIVE SGLT2 INHIBITOR, IMPROVED GLYCEMIC CONTROL OVER 2 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Kasichayanula, S.
    Griffen, S. C.
    Chalamandaris, A.
    LaCreta, F.
    Boulton, D. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S19 - S20
  • [46] Combination therapy with a SGLT2 inhibitor and a DPP-4 inhibitor suppresses macrophage foam cell formation in type 2 diabetic mice
    Terasaki, M.
    Hiromura, M.
    Kohashi, K.
    Kushima, H.
    Mori, Y.
    Hirano, T.
    DIABETOLOGIA, 2016, 59 : S30 - S30
  • [47] CETP and SGLT2 inhibitor combination therapy increases glycemic control: a 2x2 factorial Mendelian randomization analysis
    Khomtchouk, Bohdan B.
    Sun, Patrick
    Maggio, Zane A.
    Ditmarsch, Marc
    Kastelein, John J. P.
    Davidson, Michael H.
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [48] Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus
    Seino, Y.
    Sasaki, T.
    Fukatsu, A.
    Ubukata, M.
    Sasaki, T.
    Kasai, Y.
    Sakai, S.
    Samukawa, Y.
    DIABETOLOGIA, 2013, 56 : S384 - S384
  • [49] Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
    Komoroski, B.
    Vachharajani, N.
    Feng, Y.
    Li, L.
    Kornhauser, D.
    Pfister, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) : 513 - 519
  • [50] Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design
    Cao, Xuefeng
    Zhang, Wenpeng
    Yan, Xu
    Huang, Zhi
    Zhang, Zhenqing
    Wang, Peng
    Shen, Jie
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (09) : 2170 - 2173
12345